公开(公告)号：US20200046686A1

公开(公告)日：2020-02-13

申请号：US16609249

申请日：2018-06-29

Applicant: KOWA COMPANY, LTD.

Inventor： Satoshi KOJIMA ,  Ryohei TANIGAWA

IPC: A61K31/423 ,  A61P1/16

Abstract: To provide an appropriate method of treatment with pemafibrate for a liver cirrhosis patient.The present invention relates to the use of pemafibrate in a liver cirrhosis patient.More particularly, the present invention relates to a regimen for administering a reduced dose of pemafibrate to a liver cirrhosis patient in need of treatment with pemafibrate than to persons with normal liver function.

公开(公告)号：US20180250274A1

公开(公告)日：2018-09-06

申请号：US15903279

申请日：2018-02-23

Applicant: KOWA COMPANY, LTD.

Inventor： Mitsumasa NAKAMURA ,  Satoshi KOJIMA ,  Ryohei TANIGAWA

IPC: A61K31/423 ,  A61K31/575 ,  A61P1/16

CPC classification number: A61K31/423 ,  A61K31/575 ,  A61P1/16

Abstract: The present invention relates to a pharmaceutical composition for the treatment of primary biliary cirrhosis (PBC), in which containing a therapeutically effective amount of (R)-2-[3-[[N-(benzoxazol-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy] butyric acid, a salt thereof, or a solvate thereof.